By: WeightWatchers, Rich Gamret
Obesity and related comorbid conditions like type 2 diabetes, cardiovascular disease, and musculoskeletal concerns have been increasing in prevalence and severity in recent years. The costs of treating obesity and its related conditions are also on the rise for employers, driven by medical and pharmacy claims as well as unplanned absences and lost productivity.
New medications — glucagon-like peptide-1s (GLP-1s) — are producing exciting results for patients with obesity, including significant weight loss, improved health outcomes, and improved quality of life. Paired with intensive lifestyle and behavioral programs, GLP-1s are game-changers in the treatment of obesity.
GLP-1 medications drive both costs and savings for individuals and their employers.
While the costs of GLP-1 medications are high, the costs of not addressing weight health
and the conditions associated with excess weight are higher.